Ramucirumab Beneficial in Advanced Gastric/GEJ Cancers Regardless of Age

Regardless of age, patients with advanced gastric or gastroesophageal juncture (GEJ) cancer saw a survival benefit when treated with the monoclonal antibody ramucirumab. See more from the summary at the 2017 Gastrointestinal Cancers Symposium in San Francisco.